Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06779487 | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline(BIO-RIN) | recruiting | — | 200 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06924099 | TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)(TIGER France) | recruiting | — | 430 | NovoCure Ltd.INDUSTRY | 1 |
| Apr 11, 2025 |
| clinicaltrials |
| NCT04474964 | Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.(FOR-WNT2) | recruiting | N/A | 30 | Tata Memorial CentreOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05746754 | Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis(CSI ProLong) | recruiting | N/A | 50 | University of AarhusOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | recruiting | Phase 2 | 97 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05793034 | Predictive Factors for Survival in Aggressive Meningiomas(23Men) | recruiting | N/A | 250 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05941234 | Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma(IPerGlioGEM) | recruiting | N/A | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06643000 | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis | recruiting | N/A | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05565326 | Response Assessment During MR-guided Radiation Therapy for Glioblastoma(MARGA) | recruiting | — | 20 | University of ZurichOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04903678 | Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma | recruiting | N/A | 18 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05231655 | Ex VIvo DEtermiNed Cancer Therapy(EVIDENT) | recruiting | — | 600 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06832267 | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | recruiting | N/A | 44 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06830421 | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients(PRIMA-CNS) | recruiting | Phase 3 | 340 | University Hospital FreiburgOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06140875 | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF) | recruiting | N/A | 26 | Charite University, Berlin, GermanyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04962672 | Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06113705 | Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study. | recruiting | N/A | 75 | Istituto Clinico HumanitasOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05911230 | Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases(AiD-GLIO) | recruiting | N/A | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06710249 | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema(AFBTEdema) | recruiting | Phase 2 | 20 | Peter SiesjöOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782984 | Drug Response Testing and Repurposing Using Glioblastoma Organoid | recruiting | — | 150 | Chungnam National University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | recruiting | Early Phase 1 | 15 | Zhongnan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06740955 | Hypofractionated Radiotherapy | recruiting | N/A | 420 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06737250 | NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL(POTENTIAL-P) | recruiting | Phase 2 | 33 | NOBO MedicineINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06172595 | FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma(FET PET in HGG) | recruiting | Phase 2 | 22 | Singapore General HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04648462 | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | recruiting | — | 1,500 | Maastricht Radiation OncologyOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 134 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04070040 | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | recruiting | Phase 2 | 21 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04267978 | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas | recruiting | Phase 2 | 109 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | recruiting | Phase 2 | 44 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06623565 | Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques(NEXTFRONTIER) | recruiting | N/A | 30 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06595186 | JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05943262 | Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling | recruiting | — | 100 | National Taiwan University HospitalOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01106794 | Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | recruiting | — | 100 | Children's National Research InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05990556 | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients | recruiting | N/A | 20 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06417710 | Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis(NANO-LM) | recruiting | — | 200 | University of ZurichOTHER | 3 | May 16, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05768087 | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients | recruiting | N/A | 36 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06140719 | xPedite: A Study to Expedite DIPG and DMG Research | recruiting | — | 400 | xCuresINDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06381726 | Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life | recruiting | N/A | 400 | University of MilanOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06367530 | Trilateral Retinoblastoma: Incidence and Outcomes(GS-TRIO) | recruiting | — | 4,351 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 11, 2025source: clinicaltrials